3192 results for «600»
3192 results
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
PCR Tokyo Valves 2026 Closing Ceremony
15 Feb 2026 – From PCR Tokyo Valves 2026
The Closing Ceremony marks the conclusion of this cardiology conference, providing a formal wrap-up and reflection on the key highlights and advancements presented throughout the event. It serves as an opportunity to acknowledge contributors and set the stage for future initiatives in interventional cardiology.
Team approach to structural heart disease: how to handle unexpected situations
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the multidisciplinary team approach to managing structural heart disease, focusing on responses to unexpected intraoperative and postoperative situations. It features real-world experiences from a TAVI radiologic technologist, clinical engineer, TEER sonographer, and TEER nurse, emphasizing their respective roles in addressing intraoperative events, sudden...
From diagnosis to device: decision-making and planning for mitral valve interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
This session offers a structured approach to mitral TEER, integrating advanced imaging techniques for detailed mitral valve morphology evaluation, procedural planning, and complication prediction. It highlights device selection considerations and emerging technologies to tailor interventions for complex mitral valve disease, supported by multiple case presentations and...
Healthcare professionals in the structural heart disease treatment
15 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the essential roles and contributions of various healthcare professionals involved in structural heart disease treatment. It offers insights into the unique responsibilities of medical technologists, nurses, and radiological technologists across preoperative, intraoperative, and postoperative stages, fostering collaboration and sharing practical tips to strengthen...
Complications and bailout strategies in transcatheter mitral interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses complications arising during transcatheter mitral edge-to-edge repair (TEER), focusing on identification, anticipation, and management strategies. It also highlights the importance of case selection to improve procedural safety, supported by detailed case analyses covering leaflet/device, access/septal, and hemodynamic complications.
Transcatheter electrosurgery and leaflet modification of the aortic valve
15 Feb 2026 – From PCR Tokyo Valves 2026
This session offers an expert overview of transcatheter electrosurgery and leaflet modification techniques for aortic valve interventions, focusing on TAV-in-SAV scenarios. It reviews patient selection, procedural setup, and material preparation, with detailed step-by-step guidance on BASILICA and UNICORN techniques, supported by recorded cases and troubleshooting strategies...
TAVI: new evidence and clinical trials
14 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest evidence from head-to-head clinical trials comparing contemporary TAVI devices, including detailed discussions of the LANDMARK and COMPARE trials. It also highlights ongoing and upcoming clinical trials poised to influence guideline recommendations and expand the therapeutic scope of TAVI, providing crucial insights...
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)
27 Oct 2023
Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...
Author
The greatest advance in the next 40 years would be to remove the need for angioplasty
17 May 2017
Spencer B. King performed some of the first coronary angioplasty procedures in the USA—having recently received a thank-you from the first patient that he treated. He tells The Daily Wire that the steerable guidewire, rather than the stent, was the greatest advance in angioplasty and that...
Authors :
COVID-19 vaccines: Burning questions from the community and real-world applicability
13 Jan 2021
View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)